Dr. Chagpar on Surgical Treatment of Patients With HER2+ Breast Cancer

Video

Anees B. Chagpar, MD, associate professor of Surgery (Oncology) and director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven, discusses how surgical oncologists should approach the treatment of a patient with HER2-positive breast cancer.

Anees B. Chagpar, MD, associate professor of Surgery (Oncology), director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven, Yale Cancer Center, discusses how surgical oncologists should approach the treatment of patients with HER2-positive breast cancer.

In clinical practice, Chagpar explains that she surgically treats patients the same, regardless of HER2 status. If eligible, HER2-positive patients can choose breast conservation surgery versus mastectomy with reconstruction.

However, molecular subtypes such as HER2 play a role in surgery when surgical oncologists collaborate with medical oncologists, Chagpar says. This is because patients may be eligible to enroll in neoadjuvant clinical trials that can impact their surgical treatments.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "
Minesh Mehta, MD
Ruben Olivares, MD